Genovation Health, Thermo Fisher Scientific, and XYGene Launch Strategic Co-Marketing Agreement to Expand Access to Integrated Genomic Solutions

Genovation Health has entered into a multi-year strategic co-marketing agreement with Thermo Fisher Scientific and XYGene to enhance the delivery and implementation of genomic diagnostics. The partnership aims to streamline clinical workflows by integrating genomic data directly into clinical decision support systems, addressing current challenges such as fragmented data and delayed results. This collaboration is significant for the precision medicine sector as it seeks to lower healthcare costs and improve patient outcomes through more efficient pharmacogenetic and predictive genomic testing.

The multi-year agreement focuses on creating an end-to-end solution that simplifies the integration of predictive genomic data into enterprise healthcare systems. By leveraging Thermo Fisher’s Applied Biosystems Axiom microarrays and XYGene’s workflow integration capabilities, the partnership intends to provide clinicians with real-time insights at the point of care. Genovation Health’s platform will serve as the scalable foundation for delivering these insights, aiming to improve the safety and speed of personalized medicine by reducing the delays and fragmented data often associated with current genomic workflows.

Key leaders from the involved companies emphasized the importance of making genomic medicine functional for clinicians to help their patients. Dr. Howard McLeod of Genovation Health noted that the power of genomic medicine is only realized when it effectively assists clinicians, while Shantanu Kaushikkar of Thermo Fisher highlighted the need to overcome challenges in implementing comprehensive solutions within large healthcare systems. The collaboration will involve coordinated commercial strategies, joint marketing campaigns, and integrated support systems for education, microarrays, and product deployment to ensure a seamless go-to-market alignment.

Beyond workflow improvements, the partnership includes comprehensive bioinformatics for tertiary analysis and reporting, as well as automation to reduce errors and increase throughput. Patrick Geren, CEO of XYGene, stated that the combination of Genovation’s clinical intelligence and Thermo Fisher’s lab platforms creates a transformative tool for reducing diagnostic friction. Additionally, the initiative ensures stringent data protection in alignment with regional privacy laws, supporting a wide range of applications from infectious disease panels to rare disease diagnostics and pharmacogenomics, ultimately aiming to lower healthcare costs while improving informed decision-making.